We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
Sensei Biotherapeutics, Inc.
Health Care · Biotechnology
VISTA checkpoint is a differentiated immuno-oncology target with limited competition; solnerstotug could be best-in-class if Phase 1/2 data shows durable responses in checkpoint-refractory solid tumors. Multiple pipeline shots (PIKTOR, SNS-201) provide optionality.
Nano-cap size means successful data readout could be a multi-bagger.
Pre-revenue clinical-stage biotech burning cash with no approved products; ~$27M market cap implies near-term dilution risk. VISTA pathway remains largely unvalidated commercially. Pipeline is early-stage with binary trial-outcome risk on each program.
Each weekday: the scan's ENTER setups with entry, stop and target, every new ticker teardown, and the bubble shifts that move names like this one. Free. Education, not advice.
No spam. One email per day max. Pro adds Telegram trade alerts and higher AI-assistant limits.
No major news in the last 7 days for SNSE - only listicles and opinion pieces, which we filter out by default. See everything anyway.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.